Schizophrenia- Erudite study
What is the purpose of this study?
The ERUDITE Study is evaluating the effectiveness of the investigational medication, luvadaxistat, in individuals with schizophrenia.
What study drug is being researched?
The purpose of this study is to understand whether the investigational medication is safe, how the body handles taking it (tolerability), and whether it works to improve cognitive function in study participants with schizophrenia.
Who Can Participate?
You may Qualify if:
- You're between 18 and 50 years of age
- Have a confirmed diagnosis of schizophrenia for at least 1 year
- Currently receiving antipsychotic medication for schizophrenia
- Not having a lifetime diagnosis of schizoaffective disorder, bipolar disorder, or obsessive- compulsive disorder
- Not have had an occurrence of panic disorder or depression within the past 6 months.
- Not pregnant or breastfeeding
Why should participants expect?
The total length of participation in the Erudite Study is
up to 72 weeks, which includes 12 on-site study visits and 9 telemedicine visits.
This study comprises the following periods:
- Screening – This period lasts up to 4 weeks. During this period, the study team performs tests to make sure the study is a good match for the potential participant.
- Treatment period – This period lasts 14 weeks. During this period, participants will take their assigned study treatment of either the study drug or the placebo once daily.
- Extension Period- This period last 52 weeks. During this period, participants will continue to receive the actual drug.
- Follow-up period – This period lasts 2 weeks. During this period, participants will no longer take any study treatment.